Kidney Week

Abstract: TH-PO1198

Effect of Pravastatin on Kidney Disease Outcomes in Adult Patients with Early-Stage Autosomal Dominant Polycystic Kidney Disease

Session Information

• Late-Breaking Science Posters
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

• 1201 Genetic Diseases of the Kidneys: Cystic

Authors

• Gitomer, Berenice Y., University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Berenice Y. Gitomer, PhD

• Wang, Wei, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Wei Wang, MD

• Ostrow, Anna, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Anna Ostrow, MPH

• Nowak, Kristen L., University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Kristen L. Nowak, PhD, MPH

• George, Diana, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Diana George

• Coleman, Erin R., University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Erin R. Coleman, MPH

• Patel, Nayana, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Nayana Patel, MD

• Jovanovich, Anna, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Anna Jovanovich, MD

• Klawitter, Jelena, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Jelena Klawitter, PhD

• You, Zhiying, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Zhiying You, MD, PhD

• Chonchol, Michel, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States

Michel Chonchol, MD, FASN

Background

We previously showed that pravastatin slowed the rate of increase in height adjusted total kidney volume (HtTKV) over 3-years in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). To assess whether pravastatin has similar kidney benefits in adults we performed a randomized, placebo-controlled, clinical trial in patients with ADPKD and preserved kidney function.

Methods

150 patients, aged 25-60 years with an estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73m² were randomized to receive either 40 mg/day pravastatin or a placebo over 2-years. Total kidney volume was assessed by magnetic resonance imaging and renal blood flow by magnetic resonance angiography. Kidney function was measured by iothalamate (mGFR) and estimated using a cystatin-based equation. Patients with baseline and 2-year data were included in the analyses. The primary outcome was the annual % change in HtTKV. Secondary outcomes were the annual rate of decline in mGFR and the change in renal blood flow.

Results

The mean age of patients was 40±10 years and 65% were female. Eleven subjects withdrew and 1 subject was excluded from the analyses. Among the 138 patients who completed the study, there were no significant differences in changes in HtTKV, measures of kidney function or renal blood flow between placebo and pravastatin treated patients (Table 1).

Conclusion

Pravastatin did not affect the rate of cyst growth. The minimal effects on renal blood flow observed in the study are consistent with the known effect of statins on the vasculature.

Funding

• Other U.S. Government Support